first quarter with solid sales growth in a long long time. a book-to-bill of 2.5x that is better than any other publicly traded CRO company. and continued track towards profitability.
if this was any other CRO company, the stock would be up 10%. There's just a lot of hatred towards the company now and lot of unsophisticated investors who don't understand that the most important metric is book-to-bill. As an example, CVD just got acquired and routinely runs at ~1.2-1.3x Book-to-Bill. ICLR also is around 1.3x. PRXL has ~0.9x.